Generate Biomedicines, Inc. Common Stock (GENB)vsRegeneron Pharmaceuticals Inc (REGN)
GENB
Generate Biomedicines, Inc. Common Stock
$15.30
-0.78%
HEALTHCARE · Cap: $1.97B
REGN
Regeneron Pharmaceuticals Inc
$721.05
+2.67%
HEALTHCARE · Cap: $73.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 46680% more annual revenue ($14.92B vs $31.89M). REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
GENB
Avoid16
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GENB.
Margin of Safety
+51.8%
Fair Value
$1456.29
Current Price
$721.05
$735.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.7%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : GENB
GENB has a balanced fundamental profile.
Bull Case : REGN
The strongest argument for REGN centers on Altman Z-Score, Market Cap, Profit Margin. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : GENB
The primary concerns for GENB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
GENB profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (64/100 vs 16/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Generate Biomedicines, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Generate Biomedicines, Inc. is an innovative biotechnology company focused on harnessing the power of genetic engineering to develop protein therapeutics for a range of diseases. By leveraging advanced artificial intelligence and machine learning technologies, Generate Biomedicines aims to streamline the drug discovery process, significantly reducing time and costs associated with traditional methods. The company's proprietary platform enables the rapid design and optimization of therapeutic proteins, positioning it at the forefront of the biopharmaceutical industry. With a strong commitment to improving patient outcomes, Generate Biomedicines continues to expand its pipeline and collaborate with leading partners to bring transformative treatments to market.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?